Abstract
Over the last decades, beta-blockers have been a key component of heart failure therapy. However, currently there is no method to identify patients who will benefit from beta-blocking therapy versus those who will be unresponsive or worsen. Furthermore, there is an unmet need to better understand molecular mechanisms through which heart failure therapies, such as beta-blockers, improve cardiac function, in order to design novel targeted therapies. Solving these issues is an important step towards personalized medicine. Here, we present a comprehensive transcriptomic analysis of molecular pathways that are affected by beta-blocking agents and a transcriptomic biomarker to predict therapy response.
•
Endomyocardial biopsy obtained from patients with new onset heart failure.
•
Patients are followed long-term to determine clinical outcome and prognosis.
•
Total RNA is purified from the endomyocardial biopsy specimen and subjected to microarray analysis.
•
Pathway discovery and development of transcriptomic biomarkers are determined that predict clinical response to beta-adrenergic antagonists.